Advanced ovarian cancer: what should be the standard of care?.

Author: Barbara A GOFF ¹
Author Information

1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA. bgoff@uw.edu
Publication Type:Review
Keywords: Antiangiogenesis; Chemotherapy; Clinical trials; Dose dense chemotherapy; Intraperitoneal chemotherapy; Ovarian cancer; Surgery
MeSH: Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Standard of Care
From:Journal of Gynecologic Oncology 2013;24(1):83-91
CountryRepublic of Korea
Language:English
Abstract: The standard treatment of advanced ovarian cancer is rapidly changing. As we begin to understand that epithelial ovarian cancer is a heterogeneous disease, our treatment strategies are evolving to include novel biologic drugs that specifically exploit altered pathways. Surgery remains an essential component in the treatment of ovarian cancer; however, the importance of surgical specialization and defining "optimal cytoreduction" as no visible residual disease has been further validated. Ongoing studies are defining the role of neoadjuvant chemotherapy in the upfront treatment of advanced ovarian cancer. In addition, clinical trials are evaluating intraperitoneal, dose dense, antiangiogenic drugs as well as targeted maintenance therapies which will establish new standards of care in the near future.